Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

41.87 +0.71 (+1.71%)
Streaming Delayed Price Updated: 2:02 PM EST, Nov 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 323,156
Open 41.09
Bid (Size) 41.83 (300)
Ask (Size) 41.90 (200)
Prev. Close 41.16
Today's Range 40.64 - 42.08
52wk Range 26.74 - 44.23
Shares Outstanding 63,562,303
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Xenon to Present at Upcoming Investor Conferences
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
These stocks are moving in today's after hours session ↗
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill

Performance

YTD
+4.2%
+4.2%
1 Month
+2.7%
+2.7%
3 Month
+9.8%
+9.8%
6 Month
+42.1%
+42.1%
1 Year
+0.4%
+0.4%

More News

Read More
News headline image
Xenon Reports Third Quarter 2025 Financial Results & Business Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 3, 2025 ↗
Via Benzinga
News headline image
A Look Ahead: Xenon Pharmaceuticals's Earnings Forecast ↗
Via Benzinga
News headline image
Insights into Xenon Pharmaceuticals's Upcoming Earnings ↗
Via Benzinga
News headline image
Xenon to Report Q3 2025 Financial Results on November 3, 2025
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Appoints Justin Gover to Board of Directors
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Reports Second Quarter 2025 Financial Results & Business Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Report Q2 2025 Financial Results on August 11, 2025
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For August 11, 2025 ↗
Via Benzinga
News headline image
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit ↗
Via Stocktwits
News headline image
Xenon Joins the Russell 3000® and Russell 2000® Indexes
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Crude Oil Gains 3%; US Inflation Eases In April ↗
Via Benzinga
Topics Economy
News headline image
Xenon Reports First Quarter 2025 Financial Results and Provides Business Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Xenon Pharmaceuticals Inc. - Common Shares publicly traded?
Yes, Xenon Pharmaceuticals Inc. - Common Shares is publicly traded.
What exchange does Xenon Pharmaceuticals Inc. - Common Shares trade on?
Xenon Pharmaceuticals Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Xenon Pharmaceuticals Inc. - Common Shares?
The ticker symbol for Xenon Pharmaceuticals Inc. - Common Shares is XENE on the Nasdaq Stock Market
What is the current price of Xenon Pharmaceuticals Inc. - Common Shares?
The current price of Xenon Pharmaceuticals Inc. - Common Shares is 41.87
When was Xenon Pharmaceuticals Inc. - Common Shares last traded?
The last trade of Xenon Pharmaceuticals Inc. - Common Shares was at 11/24/25 02:02 PM ET
What is the market capitalization of Xenon Pharmaceuticals Inc. - Common Shares?
The market capitalization of Xenon Pharmaceuticals Inc. - Common Shares is 2.66B
How many shares of Xenon Pharmaceuticals Inc. - Common Shares are outstanding?
Xenon Pharmaceuticals Inc. - Common Shares has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.